GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (NAS:CARA) » Definitions » Cyclically Adjusted PS Ratio

CARA (Cara Therapeutics) Cyclically Adjusted PS Ratio : 0.32 (As of Dec. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-12-14), Cara Therapeutics's current share price is $0.262. Cara Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was $0.83. Cara Therapeutics's Cyclically Adjusted PS Ratio for today is 0.32.

The historical rank and industry rank for Cara Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

CARA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.3   Med: 3.16   Max: 13.18
Current: 0.31

During the past years, Cara Therapeutics's highest Cyclically Adjusted PS Ratio was 13.18. The lowest was 0.30. And the median was 3.16.

CARA's Cyclically Adjusted PS Ratio is ranked better than
93.88% of 441 companies
in the Biotechnology industry
Industry Median: 6.12 vs CARA: 0.31

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cara Therapeutics's adjusted revenue per share data for the three months ended in Sep. 2024 was $0.047. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.83 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cara Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Cara Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Cyclically Adjusted PS Ratio Chart

Cara Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 10.02 0.91

Cara Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.06 0.91 1.09 0.31 0.37

Competitive Comparison of Cara Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Cara Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cara Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cara Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cara Therapeutics's Cyclically Adjusted PS Ratio falls into.



Cara Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Cara Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.262/0.83
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cara Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Cara Therapeutics's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.047/133.0289*133.0289
=0.047

Current CPI (Sep. 2024) = 133.0289.

Cara Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.040 99.070 0.054
201503 0.021 99.621 0.028
201506 0.038 100.684 0.050
201509 0.096 100.392 0.127
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.003 101.688 0.004
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.033 102.862 0.043
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.086 106.317 0.108
201809 0.133 106.507 0.166
201812 0.140 105.998 0.176
201903 0.111 107.251 0.138
201906 0.131 108.070 0.161
201909 0.130 108.329 0.160
201912 0.097 108.420 0.119
202003 0.173 108.902 0.211
202006 0.120 108.767 0.147
202009 0.198 109.815 0.240
202012 2.187 109.897 2.647
202103 0.039 111.754 0.046
202106 0.000 114.631 0.000
202109 0.405 115.734 0.466
202112 0.016 117.630 0.018
202203 0.090 121.301 0.099
202206 0.429 125.017 0.456
202209 0.201 125.227 0.214
202212 0.061 125.222 0.065
202303 0.114 127.348 0.119
202306 0.128 128.729 0.132
202309 0.090 129.860 0.092
202312 0.055 129.419 0.057
202403 0.039 131.776 0.039
202406 0.018 132.554 0.018
202409 0.047 133.029 0.047

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cara Therapeutics  (NAS:CARA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Cara Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cara Therapeutics Business Description

Traded in Other Exchanges
Address
400 Atlantic Street, Suite 500, Stamford, CT, USA, 06901
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Executives
Christopher Posner director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Joana Goncalves officer: Chief Medical Officer C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Scott Terrillion officer: Sec'y; Chief Compliance & G.C. C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Helen M Boudreau director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Menzaghi Frederique Ph.d. officer: VP-Research & Development C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Ryan D Maynard officer: Chief Financial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Moltke Lisa Von director C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Martin Vogelbaum director 675 ALMANOR AVE, SUNNYVALE CA 94085
Csl Ltd 10 percent owner
Jeffrey L. Ives director C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Bains Harrison M Jr director
Thomas Charles Reilly officer: Chief Financial Officer C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Vifor Fresenius Medical Care Renal Pharma Ltd. 10 percent owner RECHENSTRASSE 37, CH-9014, ST. GALLEN V8 9014
Vifor (international) Ltd 10 percent owner RECHENSTRASSE 37, ST. GALLEN V8 9000
Vifor Pharma Ltd. 10 percent owner UNTERMATTWEG 8, BERNE V8 CH-3027